245 related articles for article (PubMed ID: 25550914)
1. Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis.
Yu W; Li J; Chen L
Int J Clin Exp Med; 2014; 7(11):4051-62. PubMed ID: 25550914
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
3. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
4. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
Jian Y; Chen X; Zhou H; Zhu W; Liu N; Geng C; Chen W
Medicine (Baltimore); 2016 May; 95(19):e3521. PubMed ID: 27175647
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.
Minguela A; Vasco-Mogorrón MA; Campillo JA; Cabañas V; Remigia MJ; Berenguer M; García-Garay MC; Blanquer M; Cava C; Galian JA; Gimeno L; Soto-Ramírez MF; Martínez-Hernández MD; de la Rubia J; Teruel AI; Muro M; Periago A
Am J Cancer Res; 2021; 11(9):4438-4454. PubMed ID: 34659897
[TBL] [Abstract][Full Text] [Related]
7. 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib.
Du C; Mao X; Xu Y; Yan Y; Yuan C; Du X; Liu J; Fan H; Wang Q; Sui W; Deng S; Fu M; Li Z; Li C; Zhao J; Yi S; Liu L; Hao M; Zou D; Zhao Y; Qiu L; An G
Leuk Lymphoma; 2020 May; 61(5):1201-1210. PubMed ID: 31842644
[TBL] [Abstract][Full Text] [Related]
8. At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.
Shen M; Yang G; Li X; Geng C; Huang Z; Chen W
Leuk Lymphoma; 2021 Dec; 62(12):2992-3001. PubMed ID: 34219587
[TBL] [Abstract][Full Text] [Related]
9. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center.
Liu Z; Zeng Q; Xiang B
Medicine (Baltimore); 2021 May; 100(18):e25834. PubMed ID: 33950994
[TBL] [Abstract][Full Text] [Related]
11. Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens.
Liu X; Jia S; Chu Y; Tian B; Gao Y; Zhang C; Zheng Y; Jia W; Liu X; Yuan R; Zhang N; Feng J; Dong H; Xin X; Chang Z; Cao Z; Tang H; Gao G
Front Oncol; 2022; 12():938550. PubMed ID: 36185185
[TBL] [Abstract][Full Text] [Related]
12. Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study.
Chen H; Zhou N; Shi H; Yu W; Wu L; Zhou F
Hematology; 2023 Dec; 28(1):2177979. PubMed ID: 36794720
[TBL] [Abstract][Full Text] [Related]
13. Incidence and Prognostic Significance of High-Risk Cytogenetically Abnormalities in Multiple Myeloma Patients in Colombia.
Combariza JF; Ordúz R; Agudelo C; Hernandez S; Madera AM; León G; Avila V; Bautista L; Valdés J; Camargo C; Sanchez V; Mejía F; Moreno L; Ramirez C
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):601-607. PubMed ID: 35351414
[TBL] [Abstract][Full Text] [Related]
14. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
Grzasko N; Hajek R; Hus M; Chocholska S; Morawska M; Giannopoulos K; Czarnocki K; Druzd-Sitek A; Pienkowska-Grela B; Rygier J; Usnarska-Zubkiewicz L; Dytfeld D; Kubicki T; Jurczyszyn A; Korpysz M; Dmoszynska A
Leuk Lymphoma; 2017 Sep; 58(9):1-15. PubMed ID: 28092996
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p).
Liu J; Yang H; Liang X; Wang Y; Hou J; Liu Y; Wang J; Zhou F
Oncotarget; 2017 Sep; 8(37):62435-62444. PubMed ID: 28977957
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of prognostic implications of chromosome abnormalities algorithm for newly diagnosed multiple myeloma.
Luo T; Qiang W; Lu J; He H; Liu J; Li L; Jiang H; Fu W; Du J
Blood Sci; 2021 Jul; 3(3):78-86. PubMed ID: 35402836
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805).
Kim K; Kim JS; Yoon SS; Yoon DH; Eom HS; Lee JJ; Yim HW; Park M; Lee H; Min CK;
Int J Hematol; 2022 Jul; 116(1):110-121. PubMed ID: 35543899
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
[TBL] [Abstract][Full Text] [Related]
20. The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population.
Yu W; Guo R; Qu X; Qiu H; Li J; Zhang R; Chen L
Onco Targets Ther; 2016; 9():295-302. PubMed ID: 26834489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]